New daily pill could cut migraine days in half

NCT ID NCT06414044

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study is tracking 500 Italian adults with migraine to see how well the daily pill atogepant works in everyday life. Researchers will measure changes in monthly migraine days over a year. The goal is to find out if atogepant is a safe and effective preventive treatment for people with episodic or chronic migraine.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance

atogepant

What this could lead to

If successful, this could show that atogepant is a safe and effective daily pill to prevent migraines in real-world patients.

What could go wrong

This is an observational study, not a controlled trial, so results may be less reliable. It is also limited to Italian patients, so findings may not apply to everyone.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for MIGRAINE are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Headache Headache Disorders, Secondary migraine disorder migraine with aura migraine without aura Pain

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • Fondazione Policlinico Campus Bio-Medico

    Roma, 00128, Italy

  • SOD Centro Cefalee e Farmacologia Clinica, AOU Careggi

    Florence, 50134, Italy